There are moments in the melanoma world when a piece of research lands that makes you stop, read it twice, and think: this could be important.

This week has been one of those moments.

Moderna and Merck have announced encouraging results from a large Phase 3 trial of intismeran autogene, a personalised mRNA cancer treatment being developed alongside the immunotherapy pembrolizumab (Keytruda). The trial involved 1,137 people with high-risk melanoma whose tumours had been surgically removed, including people with Stage IIB through Stage IV disease.

And the headline is pretty remarkable.

The combination of the personalised mRNA treatment and Keytruda significantly reduced the risk of melanoma returning or spreading, compared with Keytruda alone. The companies say the trial met both its primary goal of reducing recurrence and its secondary goal of reducing distant metastasis.

For a disease that has changed so dramatically over the last decade, this is another fascinating step forward.

So what exactly is this “vaccine”?

Calling it a vaccine can be slightly misleading.

This isn’t a vaccine in the traditional sense, designed to prevent you from ever developing melanoma.Instead – it’s personalised cancer immunotherapy.

The idea is incredibly clever.

Every melanoma is genetically different. When a tumour is removed, scientists can analyse its DNA and identify mutations that are unique to that particular cancer. An algorithm then selects a number of these tumour-specific targets and creates an individualised mRNA treatment designed specifically for that patient.

The mRNA effectively gives the immune system instructions about what to look for.

The hope is that T-cells are trained to recognise those particular cancer targets and attack melanoma cells if they subsequently appear elsewhere in the body.

In other words:

Instead of giving everyone exactly the same treatment, we are increasingly looking at giving the immune system a treatment designed around the individual cancer.

That is an extraordinary concept.

Moderna’s intismeran can encode up to 34 tumour-specific neoantigens based on the patient’s tumour mutations.

The numbers are encouraging

This isn’t just laboratory science anymore.

The earlier Phase 2b KEYNOTE-942 study has now produced five-year follow-up data. In that study, people with high-risk Stage III/IV melanoma who had their cancer completely removed received either Keytruda alone or Keytruda plus intismeran.

After five years, the combination continued to show a 49% reduction in the risk of recurrence or death compared with Keytruda alone.

Even more interestingly, the risk of distant metastasis or death was reduced by 59% in the five-year analysis. There was also an encouraging trend towards improved overall survival, although that result is not yet definitive.

And that’s important.

Because with melanoma, preventing the cancer from spreading somewhere else can be just as important as preventing the original tumour from coming back.

Now comes the really exciting bit

The latest Phase 3 result is much bigger than the original Phase 2 study.

More than 1,100 people were enrolled.

The trial has now met its key objectives, showing that the combination performed better than Keytruda alone in keeping melanoma from returning and spreading. The companies have said there were no new safety concerns identified so far.

However, there is an important caveat.

We don’t yet have the complete Phase 3 dataset.

The companies have announced the positive topline result, but detailed figures—including the full overall-survival analysis—are still to come. Those results will be incredibly important in understanding exactly how much difference the treatment makes and for whom.

So, as exciting as this news is, this isn’t the time to declare victory just yet.

It’s the time to be hopeful.

And Moderna isn’t stopping there

There is another fascinating Moderna programme looking at mRNA-4359, an investigational mRNA-based treatment designed to stimulate an immune response against cancer.

Early studies are looking at people with advanced or metastatic melanoma, including people whose melanoma has stopped responding to checkpoint immunotherapy.

At Moderna’s 2026 Science Day, early results from mRNA-4359 combined with pembrolizumab showed encouraging anti-tumour activity and evidence of new T-cell responses. The programme is now moving towards further Phase 2 development.

This is particularly interesting because it moves the conversation beyond “can we stop melanoma coming back?”

It asks another question:

Can personalised mRNA treatments help people who already have advanced melanoma?

That could be a very important next frontier.

From COVID vaccine to cancer treatment

There is something almost poetic about this.

Most of us first heard about mRNA because of COVID-19 vaccines.

Now the same underlying technology is being developed to help the immune system recognise and fight cancer.

And melanoma is proving to be one of the places where this technology is being tested most aggressively.

It makes sense.

Melanoma is one of the cancers that has taught oncology just how powerful the immune system can be.

Checkpoint inhibitors such as pembrolizumab and nivolumab have already transformed the treatment of advanced melanoma by effectively taking the brakes off the immune system.

Now researchers are asking whether we can go one step further:

What if we could take the brakes off AND give the immune system a personalised target?

That is the idea behind combining immunotherapy with an individualised cancer vaccine.

From a melanoma patient’s perspective…

For me, this kind of research is more than just another headline about another drug.

I’ve lived through the evolution of melanoma treatment.

Stage 1…….Then Stage 3……Then Stage 4…… and the a recurrence!!

I’ve seen what melanoma can do. I’ve seen what immunotherapy can do. I’ve also experienced first-hand that immunotherapy isn’t some magic, side-effect-free solution. It can be incredibly powerful—and incredibly tough on the body.

That’s why I find these developments so fascinating.

We are beginning to understand that cancer isn’t simply “melanoma.”

It is your melanoma ….Your mutations…..Your tumour….. and your immune response.

And potentially, one day, your own personalised treatment.

That feels like a significant shift.

But let’s keep our feet on the ground

There is a temptation whenever a major trial produces positive results to call it a cure.

We shouldn’t.

Intismeran is still investigational. The latest Phase 3 announcement is a major milestone, but the detailed results still need to be published and scrutinised, and regulatory approval is still required before it can become routine treatment.

There are also practical questions.

• How quickly can an individualised treatment be manufactured?
• How much will it cost?
• Can healthcare systems deliver it at scale?
• Will it work equally well across different melanoma subtypes?
• And, most importantly, does it ultimately help people live longer?

Those answers matter.

But that’s exactly what clinical trials are for.

Hope is a powerful thing

When I started my melanoma journey, the treatment landscape was very different.

Today we have checkpoint inhibitors, targeted therapies, cellular therapies being explored, personalised vaccines and an understanding of tumour biology that would have seemed like science fiction not so long ago.

And now we have a Phase 3 trial suggesting that an individualised mRNA treatment can make a meaningful difference when added to immunotherapy.

That’s pretty bloody exciting.

Not because it means melanoma has been beaten – because it means the fight is continuing to evolve.

Every new successful trial adds another weapon.

Every patient who benefits from a new treatment gives researchers another piece of the puzzle.

And every breakthrough gives someone, somewhere, another reason to believe they might have more time.

For those of us living with melanoma, that’s what these headlines really mean.

More options…More knowledge …More hope.

And ultimately, perhaps, a future where a diagnosis of advanced melanoma doesn’t carry the same fear that it once did.

That’s a future worth fighting for.

One Life…… LOVE IT…… LIVE IT.

There are moments in the melanoma world when a piece of research lands that makes you stop, read it twice, and think: this could be important.

This week has been one of those moments.

Moderna and Merck have announced encouraging results from a large Phase 3 trial of intismeran autogene, a personalised mRNA cancer treatment being developed alongside the immunotherapy pembrolizumab (Keytruda). The trial involved 1,137 people with high-risk melanoma whose tumours had been surgically removed, including people with Stage IIB through Stage IV disease.

And the headline is pretty remarkable.

The combination of the personalised mRNA treatment and Keytruda significantly reduced the risk of melanoma returning or spreading, compared with Keytruda alone. The companies say the trial met both its primary goal of reducing recurrence and its secondary goal of reducing distant metastasis.

For a disease that has changed so dramatically over the last decade, this is another fascinating step forward.

So what exactly is this “vaccine”?

Calling it a vaccine can be slightly misleading.

This isn’t a vaccine in the traditional sense, designed to prevent you from ever developing melanoma.Instead – it’s personalised cancer immunotherapy.

The idea is incredibly clever.

Every melanoma is genetically different. When a tumour is removed, scientists can analyse its DNA and identify mutations that are unique to that particular cancer. An algorithm then selects a number of these tumour-specific targets and creates an individualised mRNA treatment designed specifically for that patient.

The mRNA effectively gives the immune system instructions about what to look for.

The hope is that T-cells are trained to recognise those particular cancer targets and attack melanoma cells if they subsequently appear elsewhere in the body.

In other words:

Instead of giving everyone exactly the same treatment, we are increasingly looking at giving the immune system a treatment designed around the individual cancer.

That is an extraordinary concept.

Moderna’s intismeran can encode up to 34 tumour-specific neoantigens based on the patient’s tumour mutations.

The numbers are encouraging

This isn’t just laboratory science anymore.

The earlier Phase 2b KEYNOTE-942 study has now produced five-year follow-up data. In that study, people with high-risk Stage III/IV melanoma who had their cancer completely removed received either Keytruda alone or Keytruda plus intismeran.

After five years, the combination continued to show a 49% reduction in the risk of recurrence or death compared with Keytruda alone.

Even more interestingly, the risk of distant metastasis or death was reduced by 59% in the five-year analysis. There was also an encouraging trend towards improved overall survival, although that result is not yet definitive.

And that’s important.

Because with melanoma, preventing the cancer from spreading somewhere else can be just as important as preventing the original tumour from coming back.

Now comes the really exciting bit

The latest Phase 3 result is much bigger than the original Phase 2 study.

More than 1,100 people were enrolled.

The trial has now met its key objectives, showing that the combination performed better than Keytruda alone in keeping melanoma from returning and spreading. The companies have said there were no new safety concerns identified so far.

However, there is an important caveat.

We don’t yet have the complete Phase 3 dataset.

The companies have announced the positive topline result, but detailed figures—including the full overall-survival analysis—are still to come. Those results will be incredibly important in understanding exactly how much difference the treatment makes and for whom.

So, as exciting as this news is, this isn’t the time to declare victory just yet.

It’s the time to be hopeful.

And Moderna isn’t stopping there

There is another fascinating Moderna programme looking at mRNA-4359, an investigational mRNA-based treatment designed to stimulate an immune response against cancer.

Early studies are looking at people with advanced or metastatic melanoma, including people whose melanoma has stopped responding to checkpoint immunotherapy.

At Moderna’s 2026 Science Day, early results from mRNA-4359 combined with pembrolizumab showed encouraging anti-tumour activity and evidence of new T-cell responses. The programme is now moving towards further Phase 2 development.

This is particularly interesting because it moves the conversation beyond “can we stop melanoma coming back?”

It asks another question:

Can personalised mRNA treatments help people who already have advanced melanoma?

That could be a very important next frontier.

From COVID vaccine to cancer treatment

There is something almost poetic about this.

Most of us first heard about mRNA because of COVID-19 vaccines.

Now the same underlying technology is being developed to help the immune system recognise and fight cancer.

And melanoma is proving to be one of the places where this technology is being tested most aggressively.

It makes sense.

Melanoma is one of the cancers that has taught oncology just how powerful the immune system can be.

Checkpoint inhibitors such as pembrolizumab and nivolumab have already transformed the treatment of advanced melanoma by effectively taking the brakes off the immune system.

Now researchers are asking whether we can go one step further:

What if we could take the brakes off AND give the immune system a personalised target?

That is the idea behind combining immunotherapy with an individualised cancer vaccine.

From a melanoma patient’s perspective…

For me, this kind of research is more than just another headline about another drug.

I’ve lived through the evolution of melanoma treatment.

Stage 1…….Then Stage 3……Then Stage 4…… and the a recurrence!!

I’ve seen what melanoma can do. I’ve seen what immunotherapy can do. I’ve also experienced first-hand that immunotherapy isn’t some magic, side-effect-free solution. It can be incredibly powerful—and incredibly tough on the body.

That’s why I find these developments so fascinating.

We are beginning to understand that cancer isn’t simply “melanoma.”

It is your melanoma ….Your mutations…..Your tumour….. and your immune response.

And potentially, one day, your own personalised treatment.

That feels like a significant shift.

But let’s keep our feet on the ground

There is a temptation whenever a major trial produces positive results to call it a cure.

We shouldn’t.

Intismeran is still investigational. The latest Phase 3 announcement is a major milestone, but the detailed results still need to be published and scrutinised, and regulatory approval is still required before it can become routine treatment.

There are also practical questions.

• How quickly can an individualised treatment be manufactured?
• How much will it cost?
• Can healthcare systems deliver it at scale?
• Will it work equally well across different melanoma subtypes?
• And, most importantly, does it ultimately help people live longer?

Those answers matter.

But that’s exactly what clinical trials are for.

Hope is a powerful thing

When I started my melanoma journey, the treatment landscape was very different.

Today we have checkpoint inhibitors, targeted therapies, cellular therapies being explored, personalised vaccines and an understanding of tumour biology that would have seemed like science fiction not so long ago.

And now we have a Phase 3 trial suggesting that an individualised mRNA treatment can make a meaningful difference when added to immunotherapy.

That’s pretty bloody exciting.

Not because it means melanoma has been beaten – because it means the fight is continuing to evolve.

Every new successful trial adds another weapon.

Every patient who benefits from a new treatment gives researchers another piece of the puzzle.

And every breakthrough gives someone, somewhere, another reason to believe they might have more time.

For those of us living with melanoma, that’s what these headlines really mean.

More options…More knowledge …More hope.

And ultimately, perhaps, a future where a diagnosis of advanced melanoma doesn’t carry the same fear that it once did.

That’s a future worth fighting for.

One Life…… LOVE IT…… LIVE IT.